moclobemide has been researched along with rasagiline in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, G; Huang, G; Zhou, S | 1 |
| Duarte, P; Estrada-Valencia, M; Fernández-Mendívil, C; Herrera-Arozamena, C; León, R; Lombardía, J; López, MG; López-Caballero, P; Michalska, P; Morales-García, JA; Pérez, C; Pérez-Castillo, A; Rodríguez-Franco, MI; Sastre, ED; Senar, S | 1 |
2 other study(ies) available for moclobemide and rasagiline
| Article | Year |
|---|---|
Design, synthesis and biological evaluation of lazabemide derivatives as inhibitors of monoamine oxidase.
Topics: Animals; Brain; Carbon-13 Magnetic Resonance Spectroscopy; Dopamine; Drug Design; Female; Inhibitory Concentration 50; Male; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Norepinephrine; Picolinic Acids; Proton Magnetic Resonance Spectroscopy; Rats; Serotonin; Spectrometry, Mass, Electrospray Ionization; Structure-Activity Relationship | 2018 |
Resveratrol-Based MTDLs to Stimulate Defensive and Regenerative Pathways and Block Early Events in Neurodegenerative Cascades.
Topics: Antioxidants; Ligands; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Neuroprotective Agents; Oxidative Stress; Resveratrol | 2022 |